Treatment of Metastatic Esophageal Adenocarcinoma

Introduction to Treatment Guidelines

The European Society for Medical Oncology (ESMO) recommends a combination of platinum/fluoropyrimidine (cisplatin/5-FU) as palliative therapy for metastatic esophageal adenocarcinoma, considering the patient's underlying condition of ulcerative colitis, which may affect tolerance to chemotherapy 1, 2, 3, 4

Patients with liver metastases are classified as stage IV (metastatic disease), and the treatment objective is palliative, aiming to prolong survival, control symptoms, and maintain quality of life 1, 2, 3, 4
Chemotherapy is indicated for selected patients with good performance status 1, 2, 3, 4, 5

Cisplatin/5-FU is a standard combination for metastatic esophageal adenocarcinoma, with a response rate of 25-35% 1, 2, 3, 4
The ESMO guidelines recommend this regimen as the best option for adenocarcinoma with metastases 1, 2, 3, 4

Patients with ulcerative colitis have a higher risk of developing severe diarrhea and colitis due to chemotherapy, particularly with irinotecan-based regimens 6, 7, 8
5-FU infusion is safer than bolus regimens due to a better toxicity profile, especially for patients with underlying gastrointestinal conditions 6, 7
Capecitabine (oral fluoropyrimidine) should be used with caution in patients with ulcerative colitis, as it may exacerbate diarrhea 6, 7, 8

Regular evaluation (every 2 months) is essential to assess the possibility of converting to resectable disease 9
If liver metastases become resectable after chemotherapy, surgical resection can be considered to improve survival 9

Response evaluation should be performed through symptomatic evolution, endoscopy, and CT scans 3, 4
Focus on symptom control, nutrition, and psychosocial issues during follow-up 1, 2, 3, 4
Brachytherapy (single dose of 12 Gy) can provide long-term improvement with fewer complications compared to stenting for dysphagia 1, 2, 3, 4, 5

Avoid using irinotecan-based regimens as first-line treatment in patients with active ulcerative colitis due to the high risk of severe diarrhea and colitis 6, 7, 8
Avoid using capecitabine in patients with a history of ulcerative colitis, as it may trigger a flare 6, 7, 8
Do not neglect nutritional status, as patients with esophageal adenocarcinoma often experience malnutrition requiring aggressive nutritional intervention 1, 2
Regularly re-evaluate resectability, as some patients may become candidates for resection after chemotherapy 9, 8